A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL OF CORTICOSTEROID THERAPY

皮质类固醇治疗的随机、双盲、安慰剂对照试验

• 批准号: 8166708
• 负责人: SAUL J. KARPEN
• 金额: $ 0.85万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166708
• 关键词: Address; Adrenal Cortex Hormones; Affect; Bile fluid; Biliary; Biliary Atresia; Child; Childhood; Cholestasis; Clinical; Clinical Research; Clinical Trials; Complex; Computer Retrieval of Information on Scientific Projects Database; Data; Development; Diagnosis; Disease; Drainage procedure; Environmental Risk Factor; Epidemiology; Epithelium; Etiology; Extrahepatic Bile Ducts; Fibrosis; Funding; Genetic; Grant; Infant; Inflammatory; Institution; Medical; Modeling; Outcome; Pathogenesis; Patients; Phase; Process; Randomized; Research; Research Infrastructure; Research Personnel; Resources; Sampling; Source; Testing; United States National Institutes of Health; base; biliary tract; double-blind placebo controlled trial; improved; intrahepatic; liver transplantation; postnatal; research study; trait

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Biliary atresia is the most common cause of cholestasis in infants and the most frequent indication for pediatric liver transplantation. The disease results from a destructive inflammatory process that affects intra- and extrahepatic bile ducts, leading to fibrosis and obliteration of the biliary tract. Although little is known about the etiology or pathogenesis of biliary atresia, epidemiologic and virologic studies point to a complex trait disorder, in which environmental factors trigger an inflammatory process that recognizes and abnormally targets the biliary system during a specific phase of postnatal development. Based on these data, the following unifying pathogenesis model can be preliminarily proposed: Regardless of initiating (environmental) and modifying (genetic) factors for disease development, the inflammatory and fibrosing destruction of the biliary epithelium is common to all clinical forms of biliary atresia. In this setting, the potential decrease of this inflammatory component by corticosteroid treatment may result in improved bile flow and better outcome after portoenterostomy. Therefore, in this clinical trial we propose to objectively determine whether corticosteroid treatment improves bile flow in infants with biliary atresia. The significance of the proposed trial is that it will determine whether corticosteroids are an effective medical treatment to improve bile drainage and long-term outcome, and whether its use reduces the need for liver transplantation in infants with biliary atresia. The trial will be performed by the NIH-supported Biliary Atresia Research Consortium (BARC). BARC has the infrastructure to prospectively follow a sufficiently large number of patients and to collect samples necessary for clinical research studies addressing etiology, pathogenesis, diagnosis, and treatment of children with biliary atresia. Our overall hypothesis is that therapy with corticosteroids following portoenterostomy will improve bile drainage and long-term outcome in infants with biliary atresia. This hypothesis will be tested through the following hypotheses:

这个子项目是众多研究子项目之一